Jabez Biosciences, Inc. Announced Phase 1 Clinical Trial of JBZ-001 at AACR 2025
Safety, Tolerability, and Preliminary Efficacy of JBZ-001 in Patients with Advanced Solid Tumors and Non-Hodgkin Lymphoma
Safety, Tolerability, and Preliminary Efficacy of JBZ-001 in Patients with Advanced Solid Tumors and Non-Hodgkin Lymphoma